ASCO Investor & Analyst Briefing May 30, 2015
|
|
- Ella Johnston
- 6 years ago
- Views:
Transcription
1 ASCO Investor & Analyst Briefing May 30,
2 Lonnie Moulder Co-Founder & CEO 2
3 Safe Harbor Statement Statements made in this presentation that are not descriptions of historical facts are forwardlooking statements reflecting the current beliefs and expectations of management. Forwardlooking statements are sometimes identified by words such as plan, may, will, expect, and similar expressions referencing future events, conditions or circumstances. Such forward-looking statements include statements regarding the expected timing of our rolapitant and niraparib clinical trials, our regulatory filings related thereto, and potential product launches; our expectation to have oral and IV formulations of rolapitant; our expectations regarding our intellectual property and market exclusivity rights; the potential market opportunity for our product candidates; the expected attributes and advantages of our product candidates; our expected transition to an integrated commercial state company; and our 2015 corporate goals. These forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including, among others, uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from our clinical trials, ongoing discussions with and potential actions by regulatory authorities, patient accrual rates for clinical trials, other factors affecting the timing of availability of data from or initiation of our clinical trials, uncertainties regarding competition in the markets for our product candidates, and other uncertainties that could affect the availability or commercial potential of our drug candidates, as well as the detailed risks described in our Annual Report on Form 10-K for the year ended December 31, 2014, our subsequent filings with the SEC, and our preliminary prospectus supplement dated March 2, TESARO, Inc. undertakes no obligation to update or revise any forward-looking statement for any reason. 3
4 Agenda Rolapitant CINV Market Opportunity & IV Update Niraparib Program Overview & Biomarker Strategy Immuno-Oncology Update Q&A 4
5 TESARO: Strong Financial and Strategic Position Near-Term Commercial Opportunity Late-Stage Pipeline Addresses Large Markets Balanced Product Pipeline Strong Financial Position Rolapitant 09/05/15 PDUFA Q Launch CINV: $1.5B Ovarian: $4B Breast: $1B Includes 5 Programs in Phase 2 or 3 ~$399M in Cash & Equiv. as of 03/31/15 PROVEN MANAGEMENT TEAM 5
6 TESARO: A Balanced Portfolio of Product Candidates Compound Therapeutic Area Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Registration Rolapitant Oral NK-1 receptor antagonist Rolapitant IV Niraparib PARP Inhibitor Niraparib + bevacizumab Niraparib + chemotherapy TSR-011 ALK and TRK Inhibitor TSR-042 Anti-PD-1 mab Anti-TIM-3 mab CINV in A/C-breast cancer/ MEC treated patients CINV in cisplatin (HEC) treated patients CINV in cisplatin (HEC) treated patients CINV Ovarian Cancer Maintenance (NOVA) Ovarian Cancer Treatment (QUADRA) BRCA+ Breast Cancer (BRAVO) Ovarian Cancer Maintenance (AVANOVA)* Ewing s sarcoma** NSCLC, others Various tumor types Various tumor types Anti-LAG-3 mab Anti-TIM-3/PD-1 dual reactive mab Anti-LAG-3/PD-1 dual reactive mab Undisclosed mab Various tumor types Various tumor types Various tumor types Various tumor types CINV: Chemotherapy-induced nausea & vomiting; mab: Monoclonal antibody; A/C: anthracycline/cyclophosphamide; MEC: Moderately emetogenic chemotherapy; HEC: Highly emetogenic chemotherapy; NSCLC: Non-small cell lung cancer. * In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups. ** In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration. 6
7 Rolapitant A Selective NK-1 Receptor Antagonist (RA) with a Long Half-Life in Development for the Prevention of Chemotherapy- Induced Nausea & Vomiting (CINV) 7
8 ROLAPITANT PIPELINE: Oral and IV Formulations in Development Compound Therapeutic Area Discovery Preclinical Ph 1 Ph 2 Ph 3 Registration Rolapitant Oral NK-1 receptor antagonist CINV in A/C-breast cancer / MEC-treated patients CINV in cisplatin (HEC) treated patients CINV in cisplatin (HEC) treated patients Rolapitant IV CINV 8
9 ROLAPITANT: Overview Established CINV prevention guidelines support significant unmet need and potential for additional NK-1 RA utilization Successful global registration program; September 5, 2015 PDUFA date Profile includes: Long half-life and duration of action, sustained coverage Oral and IV formulations, which will allow full market access Reduced potential for CYP3A4 drug-drug interactions Potential to be clinically meaningful product for patients and healthcare providers Composition of matter protection until 2023 U.S. exclusivity into 2028 with expected Hatch-Waxman European data / market exclusivity of (+1) years Approval and launch will transform TESARO into an integrated development and commercial stage company 9
10 ROLAPITANT: Despite Available Therapies, Significant Unmet Need Remains in CINV NCCN Guidelines Version Antiemesis Perception vs. Reality 2 in Delayed CINV 91% Agent AC combination defined as either doxorubicin or epirubicin with cyclophosphamide s Cisplatin Carboplatin 1 Cyclophosphamide >1,500mg/m 2 Doxorubicin >60mg/m 2 Dacarbazine Epirubicin >90mg/m 2 Ifosfamide >2g/m per 2 dose Mechlorethamine Streptozocin 76% 43% 59% Start before chemotherapy Serotonin (5-HT 3 ) receptor antagonist AND Steroid AND Neurokinin 1 antagonist No Delayed Nausea Perception of HCPs No Delayed Vomiting Actual Patient Experience Opportunity to Educate HCPs Regarding Antiemesis Guidelines and Actual Patient CINV Experience 1 For selected patients as appropriate. 2 J Support Oncol 2004;2(suppl 1):1-12. HCPs: Healthcare Providers. 10
11 ROLAPITANT: Community Oncology Market Study (n=135) Respondent Type Practice Setting Oncology Nurse 33% Hospital or Health-System Owned Practice 19% 67% Medical Oncologist 81% Physician- Owned Community Practice 51% of Oncologists Participating in this Market Study Reported Having an In-house Pharmacy for Oral Dispensing Source: Xcenda market research 11
12 ROLAPITANT: Two-thirds of Respondents Have Guidelines Within Their Practice That Dictate Antiemetic Prescribing Variance From Practice Guidelines 56% 34% 6% 4% 0% of the Time (Never) No More Than 10% of the Time 11% 25% of the Time More Than 25% of the Time 90% of Oncologists Vary from Practice Guidelines <10% of the Time *Respondents limited to those who indicated they have a practice formulary Source: Xcenda market research 12
13 ROLAPITANT: What Are the Top Factors That Influence the Choice of Antiemetic Regimen? Evidence of Efficacy 3.4 Practice Treatment Guidelines or Clinical Pathways 2.0 Insurance Requirements 2.0 Availability in My Practice The Most Influential Factors in Selecting Antiemetic Therapy Are Efficacy, Following Practice or Clinical Pathways, and Insurance Coverage Source: Xcenda market research 13
14 ROLAPITANT: Improvement in Delayed CINV is Viewed as the Most Important Data Point Which Patients? (N=135) Likelihood of Using Product X 50% 50% 64% Oncologists (n=90) Oncology Nurses (n=45) With Highly Emetogenic Regimens 2% With Moderately Emetogenic Regimens All Patients, if Reimbursement Was Assured Patients Who Might Have Compliance/ Adherence Issues with a Multi-day NK-1 Antagonist For Patients Who Experience Delayed CINV Despite the Use of the Currently Approved NK-1 Antagonist For Other Types of Patients Overall (n=65) Likelihood of Stocking in In-house Pharmacy 6.0 Most Important Data Point % of Respondents Felt the Data Demonstrating a Statistically Significant Improvement in Delayed CINV Was Sufficiently Encouraging to Lead Them to Use Product X Source: Xcenda market research 14
15 ROLAPITANT: Large U.S. Revenue Opportunity ROLAPITANT Peak Sales Opportunity # of Potential Doses Potential Revenue IV IV OPPORTUNITY (at $300 / Dose) 1M $300M 2M $600M 3M $900M 80% ORAL OPPORUNITY (at $450 / Dose) 0.25M $113M 0.5M $225M 0.75M $338M 20% Oral Dollar figures reflect current NK-1 RA pricing of ~$300/cycle for IV and ~$450 for oral. 15
16 ROLAPITANT: Significant Potential Value Proposition for Patients and HCPs 1 Provides potential protection from CINV for up to five days 2 Single dose administered just prior to chemotherapy 3 Reduced risk of CYP3A4-mediated drug interactions 4 Use in combination with standard dose of 5-HT 3 RA and dex 5 Oral and IV formulations in development to address entire market 6 Expanded NK-1 use supported by existing anti-emetic guidelines TESARO Is Positioned to Transform into an Integrated Development and Commercial Company *Source: IMS data and Company estimates. RA: receptor antagonist. 16
17 ROLAPITANT: U.S. Launch Planned for Q Key Commercial Strategy Success Factors Potential Profile Promotional Activities Educational Efforts Key Account Collaborations Long half-life Sustained delayed phase efficacy Reduced risk of CYP3A4 DDIs IV & oral formulations Dedicated sales force Focused, right-sized commercial organization (~120) Adherence to NCCN, ASCO guidelines Goal to increase awareness of need Focus on nurses Contracting opportunity Leverage clinical trial experience Patient support program DDIs: Drug-Drug Interactions. 17
18 Mary Lynne Hedley, Ph.D. Co-Founder, President & COO 18
19 ROLAPITANT IV: Clinical Program Overview Study # of Subjects Dosed IV Status Single Ascending Dose / Multiple Ascending Dose (SAD/MAD) 77* Complete Bioequivalence (BE) 61** Complete Open-Label Safety Dose Escalation/Cohort Expansion ~100 Ongoing Open-Label Safety Drug Interaction (DDI) ~100 Ongoing * n= 57 (SAD) and n=20 (MAD) ** N = 123 subjects (n=62 dosed orally) 19
20 ROLAPITANT IV: Bioequivalence Study Design 123 Healthy Volunteers 1:1 Randomization 200 mg Oral Rolapitant (n=62) 185 mg IV Rolapitant (n=61) Endpoints Bioequivalence, determined by AUC 0-t and AUC 0- Safety, tolerability 20
21 ROLAPITANT IV: Bioequivalence Study Results Similar Exposure (AUC) For Oral and IV Formulations 21
22 Niraparib A Potentially Best-in-Class PARP Inhibitor in Phase 3 for Ovarian and Breast Cancers 22
23 NIRAPARIB PIPELINE: A Portfolio of Opportunities Compound Therapeutic Area Discovery Preclinical Ph 1 Ph 2 Ph 3 Registration 2L Ovarian Cancer Maintenance (NOVA) Niraparib Ovarian Cancer Treatment (QUADRA) 1L Ovarian Cancer Maintenance (PRIMA) To Begin 2H 2015 BRCA+ Breast Cancer (BRAVO) Niraparib + pembrolizumab Triple Negative Breast & Ovarian Cancers To Begin 2H 2015 Ovarian Cancer Niraparib Maintenance + bevacizumab (AVANOVA) Niraparib + chemotherapy Ewing s sarcoma 23
24 NIRAPARIB: Key Phase 1 Results Phase 1 RECIST Response Data 75% Platinum Sensitive HGSOC at Phase 3 Dose (300 mg) 46% Platinum- Sensitive HGSOC Across All Doses 50% 50% Platinum- Sensitive gbrcamut HGSOC Across All Doses BRCA-Positive Breast Cancer Patients Across All Doses Durable responses >1 year in platinum sensitive ovarian patients, regardless of gbrcamut status 431 days in gbrca+ patients 444 days in gbrca- patients Heavily pre-treated patient population Median prior systemic regimens: 6 in ovarian patients 5 in breast patients AE profile typical for PARPi class DLT of thrombocytopenia Highly Compelling Response Rates and Durations in Heavily Pretreated Patients HGSOC: High grade serous ovarian cancer. DLT: Dose limiting toxicity. 24
25 NIRAPARIB: Building an Ovarian Cancer Franchise 2nd Line (Recurrent) Maintenance NOVA Trial PFS primary endpoint Efficacy analyses in prespecified gbrca mut and nongbrca/hrd+ patients Data expected in Q Ovarian Treatment QUADRA Trial ORR primary endpoint Efficacy analyses in prespecified gbrca mut and HRD+ subgroups Phase 2 trial ongoing Initial data expected in early st Line Maintenance PRIMA Trial PFS primary endpoint Will enroll gbrca mut and HRD+ patients Phase 3 trial to begin 2H 2015 AVANOVA and anti-pd-1 mab Combination Trials Will Further Characterize Niraparib in Ovarian Cancer PFS: Progression free survival. ORR: Overall response rate. HRD: Homologous recombination deficiency. 25
26 NIRAPARIB: MyChoice HRD Test Can Discriminate High vs. Low HRD Tumors HRD Distribution of 561 Ovarian Tumors: BRCA Deficient Tumors Include Germ Line, Somatic and BRCA Promoter Methylated 26
27 NIRAPARIB: HRD Scoring of Breast and Ovarian Patient-Derived Xenografts 4.5 BRCA1 met 3.5 BRCA2 mut BRCA1 mut BRCA wt HRD score Sensitive to niraparib Resistant to niraparib HRD Score Identifies Niraparib Sensitive and Resistant Tumors; Equivalent Response Rates Observed in HRD+ and BRCA Mutant Tumors 27
28 NIRAPARIB: Phase 3 Trial in 2 nd Line (Recurrent) Ovarian Cancer Maintenance (NOVA Trial) High Grade Serous Ovarian Cancer, Platinum Sensitive, Relapsed Response to Platinum Treatment n=490 gbrca mut Non-gBRCA mut / HRD 2:1 Randomization 2:1 Randomization Niraparib 300 mg Placebo Niraparib 300 mg Placebo n=120 n=60 n=207 n=103 Endpoint Assessment Endpoint Assessment Primary Endpoint PFS; >90% power to detect 4.5 month improvement (HR 0.50 in both cohorts) Assumption: 4.5 month PFS for control arms Expanded enrollment of non-gbrcamut cohort to complete 1Q PFS: Progression free survival. TNBC: Triple negative breast cancer. HRD: Homologous recombination deficiency. 28
29 NIRAPARIB: Preliminary HRD Distribution in NOVA Tumors HRD Distribution of gbrcamut Tumors HRD Distribution of 106 Tumors from Non-gBRCA mut Cohort gbrca mut cohort 16 BRCA wild type Tumor BRCA1 mut Number of tumor samples Number of tumor samples HRD score HRD score Nearly All gbrca and tbrca Mutant Tumors Have High HRD Scores; A total of 57% of the non-gbrca mut cohort have deficiencies in HR 29
30 NIRAPARIB: Approximately 2/3 of Patients Enrolled in the Phase 3 NOVA Trial are HRD+ HRD Biomarker Negative (~1/3) nongbrca mut ~65% gbrca mut ~35% HRD+ (~2/3) Overall, approximately 35% of patients enrolling into NOVA are gbrca mutant and 65% are non-gbrca mutant Nearly all patients who have a gbrca mutation have a positive HRD score Approximately half of patients who are non-gbrca mut are projected to be HRD+ Data Presented at ASCO 2015 Meeting 30
31 NIRAPARIB: Announced Today: Clinical Collaboration with Merck Phase 1/2 trial of niraparib plus KEYTRUDA (pembrolizumab) Goal to evaluate preliminary safety and efficacy of this combination Plan to enroll patients with triple-negative breast cancer or ovarian cancer Response rates with anti-pd-1 mab monotherapy: 11.5% in ovarian cancer (1) 18.5% in triple negative breast cancer (2) External expenses to be shared equally Collaboration led by joint development committee Expected to begin by YE 2015 Pembrolizumab data presentations: 1 Results from Varga et. al, ASCO 2015; pembrolizumab abstract #5510; best overall (confirmed) response (keynote-012). 2 Results from Nanda R., et.al., San Antonio Breast Cancer Symposium 2014; pembrolizumab abstract SI-09; overall response. KEYTRUDA is a trademark of Merck & Co., Inc. 31
32 NIRAPARIB: Combination Therapy: Rationale for Combining PARPi and Anti-PD-1 Niraparib Plus Anti-PD-1 in TNBC Two Non-mutually Exclusive Hypotheses 1. PARPi can trigger cell death and increased inflammation and consequently increased CD8+ TILs with immune checkpoint modulators 2. PARPi will selectively increase somatic mutations in tumors and result in neo-antigens which will trigger CD8+ TILs with immune checkpoint modulation Cell deathmediated inflam. Experimental Pre-clinical Data is Available Indicating the Potential for Synergy with PARPi and Immune Checkpoint Inhibitors 1. Veliparib has demonstrated synergy with anti- CTLA-4 in BRCA deficient pre-clinical models 2. Niraparib has demonstrated synergy with anti-pd-1 in a preclinical syngeneic model Neoantigens Immunosurveillance 32
33 NIRAPARIB: Potential Value Proposition 1 2 Compelling RECIST response rate and durability in heavily pre-treated patients Convenient, once per day oral dosing 3 Broad development program in ovarian cancer 4 Broad development program in breast cancer 5 Biomarker incorporation potentially allows for patient selection 6 Potential for combinations with immuno-oncology and other targeted agents 33
34 Immuno-Oncology Portfolio Monospecific Antibodies Targeting PD-1, TIM-3 and LAG-3 Plus Dual Specific Antibodies Targeting PD-1/TIM-3 and PD-1/LAG-3 34
35 Immuno-Oncology: Advancing Our Early Stage Pipeline Compound Indication Discovery Preclinical Ph 1 Ph 2 Ph 3 Registration TSR-042 Anti-PD-1 mab Anti-TIM-3 mab Various tumor types Various tumor types Anti-LAG-3 mab Anti-TIM-3/PD-1 dual reactive mab Anti-LAG-3/PD-1 dual reactive mab Undisclosed mab Various tumor types Various tumor types Various tumor types Various tumor types 35
36 Immuno- Oncology: TESARO s Vision & Strategy TESARO s I-O portfolio: Three known checkpoint inhibitors PD-1, TIM-3 and LAG-3 Three bi-specific antibodies PD-1/TIM3 and PD-1/LAG-3 Additional undisclosed bispecific Immune modulators are likely to treat many tumor types May be most effective when used in combination therapy Potential to combine with TESARO pipeline molecules Establish collaborations with other companies that have complementary approaches 36
37 Immuno- Oncology: TSR-042: A Potent Anti-PD-1 Antibody Biacore Binding Kinetics to Human PD-1 Blocks PD-L1 and PD-L2 Binding to PD-1 in a Competitive Cell Based Assay PD-L1 or PD-L2 -DyL650 TSR-042 Backup PD-1 CHO TSR-042 Backup K D 2.4 nm 6.7 nm Ligand TSR-042 (IC50) Backup (IC50) PD-L1-DyL nm 2.1 nm PD-L2-DyL nm 1.8 nm 37
38 Immuno- Oncology: TSR-042 Enhances Activation of Human T Cells Increased IL-2 Production in MLR Assay 2,000 IL-2 Concentration (pg/ml) 1,500 1, No Antibody mab (nm) TSR-042 Backup Isotype Control EC 50 67pM 133pM 38
39 Immuno- Oncology: Anti-TIM-3 Antibodies Enhance Activation of Human T Cells Increased IL-2 Production in T Cell Activation Assay 2,000 IL-2 Concentration (pg/ml) 1,500 1, mab (nm) Anti-TIM-3 Lead Anti-TIM-3 Back up IgG Control EC nm 3.0 nm 39
40 Immuno- Oncology: Anti-TIM-3 Antibody Further Enhances Anti-PD-1 Activation of Human T Cells Increased IL-2 Production in Combination with Anti-PD-1 in MLR Assay 3,000 IL-2 Concentration (pg/ml) 2,000 1, mab (nm) Anti-TIM ng/ml anti-pd-1 Anti-TIM ng/ml anti-pd-1 Anti-TIM-3 Lead EC nm 0.47 nm 3.0 nm 40
41 Immuno- Oncology: Optimized Tumor Regression with Combination Anti-TIM3 and Anti-PD1 in the MC38 Model PBS Anti-TIM3 Tumor Volume (mm 3 ) Tumor Volume (mm 3 ) Days Post Randomization Days Post Randomization Anti-PD1 Anti-TIM3 + Anti-PD1 Tumor Volume (mm 3 ) Tumor Volume (mm 3 ) Days Post Randomization Days Post Randomization = DOSING DAYS. Note: Each antibody dosed at 10mg/kg on days 1, 4, 8 and 11 post randomization. 41
42 Immuno- Oncology: Anti-LAG-3 Antibodies Enhance Activation of Human T Cells Increased IL-2 Production in MLR Assay 2,000 IL-2 Concentration (pg/ml) 1,500 1, mab (nm) Anti-LAG-3 Lead Anti-LAG-3 Reference Anti-LAG-3 Reference EC nM 6.0nM 3.0nM 42
43 Immuno- Oncology: Anti-LAG-3 Antibody Further Enhances Anti-PD-1 Activation of Human T Cells Increased IL-2 Production in Combination with Anti-PD-1 in MLR Assay 3,000 IL-2 Concentration (pg/ml) 2,000 1, mab (nm) Anti-LAG ng/ml anti-pd-1 Anti-LAG ng/ml anti-pd-1 Anti-LAG-3 alone EC pm 27 pm 800 pm 43
44 Immuno- Oncology: Optimized Tumor Regression with Combination Anti-LAG3 and Anti-PD1 in the Colon26 Model PBS Anti-PD-1 Anti-LAG Tumor Volume (mm 3 ) Tumor Volume (mm 3 ) Tumor Volume (mm 3 ) Days Post Tumor Inoculation Days Post Tumor Inoculation Days Post Tumor Inoculation Anti-LAG-3 + anti-pd-1 Tumor Volume (mm 3 ) Days Post Tumor Inoculation Tumor Re-challenge Day 85 = DOSING DAYS. Note: Each antibody dosed at 10mg/kg on days 4, 7, 11 and 14 post tumor inoculation. 44
45 Immuno- Oncology: Summary: TESARO s Immunotherapy Antibody Program PD-1, LAG-3 and TIM-3 Are Key Immune Checkpoint Receptors That Negatively Regulate T Cell Activation Exhausted T cell Reinvigorated T cell Cytokines Effector mechanisms Additional combination studies ongoing IND for anti-pd-1 antibody targeted for EOY 2015 Anti-TIM-3 and anti-lag-3 antibodies targeted for INDs in 2016 Activation signal TCR Ag MHC Inhibitory signal PD-1 LAG-3 TIM-3 Activation signal TCR Ag MHC αpd-1 αtim-3 αlag-3 Bispecific Lead generation in progress Anti-LAG-3/anti-PD-1 Anti-TIM-3/anti-PD-1 Undisclosed APC or Tumor Cell APC or Tumor Cell 45
46 Lonnie Moulder Co-Founder & CEO 46
47 TESARO: 2015 Is a Transformative Year Rolapitant Niraparib Early Stage Pipeline Establish a full-scale oncology U.S. commercial organization by end of Q Oral rolapitant PDUFA goal date September 5, 2015 Launch oral rolapitant in Q4 2015, pending regulatory approval Submit NDA for IV rolapitant following commercial launch of oral rolapitant Advance the QUADRA trial Report data from NOVA in Q Advance the BRAVO trial Initiate PRIMA trial, pembrolizumab combination trial, and SCLC trial in 2H 2015 Enroll additional ALK+, ALKi-naïve patients to enable registration decision Submit IND for TSR-042 by year end Advance IND enabling studies for anti-tim-3 and anti-lag-3 clinical candidates NDA: New Drug Application. IV: Intravenous. SCLC: Small cell lung cancer. IND: Investigational New Drug. 47
48 Q&A 48
49 ASCO Investor & Analyst Briefing May 30,
50 Appendix 50
51 NIRAPARIB: Registration Trial for Treatment of Ovarian Cancer (QUADRA Trial) High Grade Serous Ovarian Cancer, Platinum Resistant or Platinum Sensitive, gbrca mut or HRD Received 3 or More Lines of Chemotherapy N=225 Niraparib 300 mg Daily Treatment Endpoint Assessment Primary Endpoint Overall Response Rate (ORR) 51
52 NIRAPARIB: Phase 3 Trial in 1 st Line Ovarian Cancer Maintenance (PRIMA Trial) High Grade Serous Ovarian Cancer Responded to 1 st Line Platinum Chemotherapy, with No Evidence of Progression, No Disease >2cm and Normal CA125 Tumor Biomarker Positive Ovarian Cancer 2:1 Randomization Niraparib N=192 Placebo N=96 Primary Endpoint PFS Power assumptions: 13* vs. 20 months, HR=0.625, 90% power *Control from ICON 7, OVAR 16 and erlotinib studies. 52
53 NIRAPARIB: PARP Inhibitor Peak Market Opportunity in Ovarian Cancer of Approximately $4 Billion United States Europe 2L (Recurrent) Maintenance 2L (Recurrent) Maintenance Treatment Treatment 1L Maintenance 1L Maintenance Patients (000s) Patients (000s) gbrca mut Non-gBRCA mut /HRD + Non-gBRCA mut / HRD- Other/Ineligible Approximately 40,000 Eligible Patients in the U.S. and Europe 1L: 1st Line; 2L: 2nd Line; Treatment: 3 or more lines of previous therapy. Dollar figures reflect current PARP inhibitor pricing. Source: Company estimates. 53
54 NIRAPARIB: PARP Inhibitor Peak Market Opportunity in gbrca mut Breast Cancer Exceeds $1 Billion U.S. Europe gbrca mut Patients (000s) 1L Patients 2L Patients 3L Patients Approximately 20,000 Eligible Patients in the U.S. and Europe 1L: 1st Line metastatic/recurrent; 2L: 2nd Line metastatic; 3L: 3rd Line metastatic. Dollar figures reflect current PARP inhibitor pricing. Source: Company estimates. 54
55 Immuno- Oncology: Generating Antibodies with In Vitro Somatic Hypermutation SHM-XEL System for Ab Discovery & Optimization Harnessing the natural mechanism of antibody maturation in vitro Starting Library Evolving Library More evolved Library Evolved Library Ab genes have evolved to use SHM for efficient selection of high affinity Abs Mammalian cell display of intact, fully-functional IgG Allows selection of antibodies in their native format Co-selection for high expression level and developability parameters High throughput selection using FACs 55
56 Immuno- Oncology: Optimal Therapeutic Antibody Properties Controlled Selection for Optimal Therapeutic Properties Affinity Functionality Human Species Cross-Reactivity Sequences Expression Biophysical Properties To low pm KD values e.g., neutralization, signaling, apoptosis induction, effector functions Low immunogenic potential To facilitate preclinical toxicology V-region glycosylation sites, deamidation & isomerization motifs etc. Well expressed in mammalian cells e.g., thermal stability, solubility, aggregation propensity AnaptysBio Technology Allows Selection for Optimal Properties and Circumvents the Need to Isolate Large Panels of Screening Antibodies 56
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCORPORATE PRESENTATION. March 2017
CORPORATE PRESENTATION March 2017 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationAccelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO
Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO 3 December 2018 Cautionary statements This presentation may contain forward-looking statements. Forward-looking
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCompany Update. September 2016
Company Update September 2016 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationASCO Investor & Analyst Briefing. June 3, 2017
ASCO Investor & Analyst Briefing June 3, 2017 Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationEvercore ISI Conference November 29, 2017
Evercore ISI Conference November 29, 2017 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationFDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors
FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors Diana Brixner, PhD, RPh, FAMCP Professor, University of Utah Health Sciences Executive Director, Pharmacotherapy Outcomes
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationNew Data from Ongoing Melanoma Study and Clinical Development Strategy Update
New Data from Ongoing Melanoma Study and Clinical Development Strategy Update Webcast - 29 th / 30 th May 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements The purpose of the presentation
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationCompany Update. November 2015
Company Update November 2015 Legal Disclaimer This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More information